An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 021641
Company: TEVA

Summary Review

Products on NDA 021641

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
AZILECT	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	AB	Yes	No
AZILECT	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 021641

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
05/16/2006	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021641s000LTR.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021641s000_AzilectTOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/16/2020	SUPPL-21	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021641s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021641Orig1s021ltr.pdf
12/20/2018	SUPPL-20	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021641s020lbl.pdf
12/09/2015	SUPPL-19	Manufacturing (CMC)		Label is not available on this site.
07/20/2015	SUPPL-18	Manufacturing (CMC)		Label is not available on this site.
05/29/2014	SUPPL-17	Efficacy-New Indication	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021641Orig2s016,s017ltr.pdf
05/29/2014	SUPPL-16	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021641Orig2s016,s017ltr.pdf
12/09/2009	SUPPL-10	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf
12/09/2009	SUPPL-8	Efficacy-Labeling Change With Clinical Data	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008TOC.html https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021641S008_SumR.pdf
12/09/2009	SUPPL-7	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf
12/09/2009	SUPPL-5	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf
12/09/2009	SUPPL-4	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf
12/09/2009	SUPPL-3	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf
12/09/2009	SUPPL-2	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021641s002s003s004s005s006s007s008s010ltr.pdf

Labels for NDA 021641

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/16/2020	SUPPL-21	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021641s021lbl.pdf
12/20/2018	SUPPL-20	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021641s020lbl.pdf
05/29/2014	SUPPL-17	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf
05/29/2014	SUPPL-16	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021641s016s017lbl.pdf
12/09/2009	SUPPL-10	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-8	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-7	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-5	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-4	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-3	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
12/09/2009	SUPPL-2	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
05/16/2006	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021641lbl.pdf

Therapeutic Equivalents for NDA 021641

AZILECT

TABLET;ORAL; EQ 0.5MG BASE
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
AZILECT	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	Yes	AB	021641	TEVA
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	201889	ALKEM LABS LTD
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	201971	AUROBINDO PHARMA USA
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	201942	CARNEGIE
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	201892	CHARTWELL RX
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	208866	MACLEODS PHARMS LTD
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	207004	MICRO LABS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	201970	ORBION PHARMS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	206153	REGCON HOLDINGS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	218163	RISING
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 0.5MG BASE	TABLET;ORAL	Prescription	No	AB	210150	TORRENT

TABLET;ORAL; EQ 1MG BASE
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
AZILECT	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	Yes	AB	021641	TEVA
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	201889	ALKEM LABS LTD
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	201971	AUROBINDO PHARMA USA
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	201942	CARNEGIE
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	201892	CHARTWELL RX
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	208866	MACLEODS PHARMS LTD
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	207004	MICRO LABS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	201970	ORBION PHARMS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	206153	REGCON HOLDINGS
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	218163	RISING
RASAGILINE MESYLATE	RASAGILINE MESYLATE	EQ 1MG BASE	TABLET;ORAL	Prescription	No	AB	210150	TORRENT

Top